Startup
Dresden-based Seamless Therapeutics has concluded a major strategic agreement with Eli Lilly and Company.
Jan 29, 2026
At the center of the deal is treating hearing impairment. Seamless specializes in high-precision DNA recombinases – genetic recombination enzymes – to correct flaws that cause hearing loss.
The deal sees Lilly providing the young Dresden firm with access to up to USD 1.12 billion for research and development.
“This collaboration is confirmation of our gene-editing platform and its broad potential for…
